New Anticoagulants: Anti-IIa or Anti-Xa Agents?
The iatrogenicity of vitamin K antagonists is well established. Each year in France, vitamin K antagonists account for more than 17,000 hospital admissions and nearly 4000 deaths. Alternative treatment would be more than welcome. It is hard to imagine a drug that would induce more complications than a vitamin K antagonist.
KeywordsDeep Vein Thrombosis Dabigatran Etexilate Enoxaparin Group Rivaroxaban Group Oral Thrombin Inhibitor
Unable to display preview. Download preview PDF.
- 1.Bauer KA (2001) Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm 58 (Suppl 2):S14–17Google Scholar
- 18.Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R (2005) A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 3: 103–111CrossRefPubMedGoogle Scholar
- 21.The RE-MOBILIZE Writing Committee (2009) Oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 24: 1–9Google Scholar